Anti-Phosphohistone H3-Positive Mitoses Are Linked to Pathological Response in Neoadjuvantly Treated Breast Cancer

Publisher： Karger

E-ISSN： 1661-3805|12|4|244-250

ISSN： 1661-3791

Source： Breast Care, Vol.12, Iss.4, 2017-08, pp. : 244-250

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Therapy Standards in HER2-Positive Breast Cancer

By  

Breast Care, Vol. 11, Iss. 2, 2016-04 ,pp. : 148-150

Karger

Access to resources Recommend Favorite

Pathological Workup of Surgical Breast Cancer Specimens after Neoadjuvant Chemotherapy

By  

Breast Care, Vol. 1, Iss. 6, 2006-12 ,pp. : 368-373

Karger

Access to resources Recommend Favorite

Anti-HER2 Therapy Beyond Second-Line for HER2- Positive Metastatic Breast Cancer: A Short Review and Recommendations for Several Clinical Scenarios from a Spanish Expert Panel

By  

Breast Care, Vol. 11, Iss. 2, 2016-02 ,pp. : 133-138

Karger

Access to resources Recommend Favorite

Node-Positive Breast Cancer: Which Are the Best Chemotherapy Regimens?

By  

Breast Care, Vol. 3, Iss. 4, 2008-08 ,pp. : 244-250

Karger

Access to resources Recommend Favorite

Extended Adjuvant Endocrine Therapy in Hormone Receptor-Positive Early Breast Cancer

By  

Breast Care, Vol. 12, Iss. 3, 2017-06 ,pp. : 138-144

Karger

Access to resources Recommend Favorite